VIR 576

Drug Profile

VIR 576

Alternative Names: VIR-576; VIR-576 anchoring inhibitor - VIRO Pharmaceuticals GmbH

Latest Information Update: 21 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VIRO Pharmaceuticals
  • Class Antiretrovirals
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 11 May 2010 Phase-I/II clinical trials in HIV infections in Germany (IV infusion)
  • 11 May 2010 Efficacy & adverse events data from a phase I/II trial in HIV infections presented at the 12th European AIDS conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top